Latest Risk Management News

Sequoia Financial Group has launched a dedicated AFSL Governance Committee to bolster oversight across its licenses, appointing former ASIC Commissioner Danielle Press as Independent Chair.

Horizon Oil has completed its acquisition of significant interests in two producing gas fields in Thailand, adding 2,100 barrels of oil equivalent per day to its portfolio and expanding its footprint in Southeast Asia.

Redcastle Resources has unveiled a positive Scoping Study for its Queen Alexandra gold project, highlighting a high-return open pit operation with near-term production potential and robust economics at current gold prices.

Pilot Energy reports significant progress in transitioning the Cliff Head Oil Field to a carbon storage facility, alongside a major upgrade in WA-481P gas and oil prospective resources and a $6.8 million capital raise.

Austin Metals reports promising gold and copper-gold drilling results at its Western Australian projects while divesting its Broken Hill assets to sharpen focus on core holdings.

MONEYME has exceeded its FY25 operating cash profit expectations by 20%, driven by robust loan book expansion and improved credit quality, while gearing up for a major credit card launch.

AMCIL Limited reported a net profit of $6.7 million for FY2025, down from $7.5 million the previous year, and announced a fully franked total dividend of 6.5 cents per share, boosted by a special capital gains payout.

Pinnacle Minerals has progressed metallurgical reviews and exploration across its rare earth, lithium, and heavy mineral sands projects, supported by a recent $1.76 million capital raising to fund ongoing and new opportunities.

Nex Metals Explorations has moved closer to finalising a joint project agreement for its Kookynie Tailings Project while navigating leadership changes and securing fresh capital to fund growth.

Latrobe Magnesium secures EPA licence extension and prepares to start magnesium oxide production in August, while pursuing a significant legal counterclaim and advancing commercial plant plans.

Prescient Therapeutics has secured FDA Fast Track designation for PTX-100 in treating relapsed Cutaneous T-Cell Lymphoma and dosed the first patient in its Phase 2a trial, supported by a recent $6.8 million capital raise.

WhiteHawk Limited reported solid Q2 revenue growth with new US contracts and is advancing its Australian market entry, while managing cash flow challenges.